CJC-1295 (with DAC)

CJC-1295 (with DAC), also known as DAC:GRF (Drug Affinity Complex:Growth Hormone-Releasing Factor), is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH). It's a peptide that was developed to stimulate the pituitary gland to release growth hormone (GH) and insulin-like growth factor 1 (IGF-1). The "with DAC" part is crucial, as it's a modification that significantly extends the peptide's half-life by binding to albumin in the bloodstream, allowing it to stay active in the body for a much longer period. This is what differentiates it from CJC-1295 without DAC (also known as Modified GRF (1-29) or CJC-1295 No DAC), which has a much shorter half-life and requires more frequent injections.

Benefits and Side Effects

Benefits:

• Increased Muscle Mass and Strength: By stimulating the release of growth hormone and IGF-1, CJC-1295 (with DAC) can promote muscle growth and improve overall body composition.

• Enhanced Fat Metabolism: It helps the body burn fat more efficiently by increasing lipolysis (the breakdown of fats) and reducing fat storage.

• Improved Recovery: It can aid in faster recovery from injuries and workouts.

• Anti-Aging Effects: Users may experience benefits like improved skin elasticity, better sleep, and increased energy levels.

• Increased Bone Density: Growth hormone and IGF-1 are known to play a role in bone health.

Side Effects:

• Injection Site Reactions: Common side effects include pain, redness, or swelling at the injection site.

• Water Retention: Increased GH levels can lead to the body retaining extra fluid, causing temporary bloating or mild swelling.

• Headaches and Dizziness: Some users report experiencing headaches or dizziness.

• Flushing: A temporary feeling of warmth or redness in the face.

• Hyperactivity: A small percentage of users may report hyperactivity.

Pros and Cons

Pros:

• Long Half-Life: The primary advantage of the DAC version is its long half-life of about 6-8 days, which means fewer injections are needed, typically once or twice a week. This is more convenient than the non-DAC version, which requires daily or multiple daily injections.

• Sustained GH Release: The long half-life leads to a more consistent and sustained elevation of GH and IGF-1 levels.

• Potent Effects: It can cause a significant increase in GH and IGF-1, leading to noticeable benefits in body composition, recovery, and overall well-being.

Cons:

• Less Flexible Dosing: The long half-life makes it difficult to adjust the dosage or stop use quickly if side effects occur.

• Potential for Prolactin Increase: While CJC-1295 itself is not known to increase prolactin, it is often combined with other peptides, such as Ipamorelin, which can have an effect on prolactin levels. It's important to note that the search results indicate that CJC-1295 alone does not increase prolactin production.

• Limited Clinical Research and Regulation: It's important to understand that CJC-1295 (with DAC) is not approved by regulatory bodies like the FDA for use outside of research settings. It was investigated for conditions like growth hormone deficiency but was discontinued during Phase II clinical trials due to the death of a trial subject. The death was not definitively linked to the drug, but research was terminated as a precaution.

Dosage and Frequency

Due to its long half-life, a typical dosage for CJC-1295 (with DAC) is 2 mg once per week. It is often administered via subcutaneous injection. However, specific dosages and frequencies can vary depending on individual needs and goals. This information is for educational purposes only and not a recommendation for use.

Half-Life and Detection Time

• Half-Life: Approximately 6-8 days in humans. The long half-life is achieved because the DAC binds to albumin, a protein in the blood, which prolongs its presence in the body.

• Detection Time: CJC-1295 is a prohibited substance under the WADA (World Anti-Doping Agency) Prohibited List. Due to its long half-life and sustained effects, it can be detectable for an extended period, though specific detection times can vary depending on the testing method.

Sterogenic, Progestogenic, Prolactin Affects, and Anabolic/Androgenic Ratio

• Sterogenic/Progestogenic Affects: CJC-1295 is a peptide hormone, not a steroid. Therefore, it does not have sterogenic or progestogenic effects.

• Prolactin Affects: According to the search results, CJC-1295 alone does not increase the production of prolactin. However, it's often used in a stack with other peptides like Ipamorelin, which can have an effect on prolactin.

• Anabolic/Androgenic Ratio: This ratio is a measure used for anabolic-androgenic steroids (AAS) to compare their anabolic (muscle-building) and androgenic (masculinizing) effects. Since CJC-1295 is not a steroid, this ratio does not apply to it.